Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy

Background: Chronic HIV is associated with increased inflammation and tissue fibrosis despite suppressive antiretroviral therapy (ART). Monocytes and macrophages have been implicated in the pathogenesis of fibrosis, facilitated by chemokine receptor interactions. Methods: We assessed systemic fibrot...

Full description

Bibliographic Details
Main Authors: S. Bowler, C. Siriwardhana, B. L. Mitchell, M. L. D’Antoni, D. Ogata-Arakaki, S. Souza, R. Yee, L. M. A. Gangcuangco, D. C. Chow, L. C. Ndhlovu, C. Shikuma
Format: Article
Language:English
Published: Taylor & Francis Group 2019-09-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
inflammation
fibrosis
chemokines
ccr2
ccr5
Online Access:http://dx.doi.org/10.1080/25787489.2020.1719319

Internet

http://dx.doi.org/10.1080/25787489.2020.1719319

Similar Items